To describe a case of bilateral cystoid macular edema in a patient with Dandy-Walker syndrome. An 18-year-old male was referred to our tertiary referral center for evaluation of his decreased visual acuity. Detailed ophthalmic examination and imaging revealed the presence of bilateral cystoid macular edema, which was successfully treated with intravitreal triamcinolone injections (2 mg in 0.05 ml). Recurrence of macular edema developed after a period of approximately four months. This is an unusual ophthalmic manifestation of Dandy-Walker syndrome. Cystoid macular edema should be included in the differential diagnosis of subjects with Dandy-Walker syndrome presenting with decreased vision. The pathogenetic mechanism for the development macular edema in this case is not clear. Intravitreal triamcinolone is an effective treatment, but edema was recurrent in our case. Other approaches (such as oral Acetazolamide or intravitreal Anti-VEGF) have to be considered as well.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/08820538.2015.1123732 | DOI Listing |
JAMA Ophthalmol
January 2025
Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha.
Importance: Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials.
Objective: To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab.
Vision (Basel)
January 2025
Department of Ophthalmology, King George's Medical University, Lucknow 226003, India.
Objectives: The goal was to study the ellipsoid zone (EZ) as a structural biomarker for final visual outcomes after pharmacological intervention in center-involving diabetic macular edema (DME) and surgical intervention for full-thickness macular holes (FTMHs).
Methods: This was a tertiary care center-based retrospective study. After sample size calculations, data from 64 consecutive cases were collected, with subjects aged between 40 and 60 years.
Surv Ophthalmol
January 2025
Department of Ophthalmology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, United States. Electronic address:
Internal limiting membrane (ILM) peeling has been an acceptable step in vitrectomy surgeries for various retinal diseases such as macular hole, chronic macular edema following epiretinal membrane (ERM), and vitreoretinal traction. Despite all the benefits, this procedure has some side effects, which may lead to structural damage and functional vision loss. Light and dye toxicity may induce reversible and irreversible retina damage, which will be observed in postoperative optical coherence tomography scans.
View Article and Find Full Text PDFAm J Ophthalmol Case Rep
March 2025
Emory Eye Center, Emory University, Atlanta, GA, USA.
Purpose: To report a case of persistent bilateral sclerouveitis following bilateral bimatoprost implantation (Durysta) that required implant removal and oral steroid course.
Observation: A 75-year-old Caucasian male with no prior ocular inflammation experienced bilateral sclerouveitis post bilateral bimatoprost implantation. Despite implant removal from both eyes, the ocular inflammation persisted, showing cystoid macular edema in both eyes and exudative retinal detachment in the right.
Heliyon
January 2025
Ophthalmology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Purpose: To evaluate the intermediate-term visual and safety outcomes of the small-incision second-generation implantable miniature telescope (SING IMT) in patients with late-stage age-related macular degeneration (AMD) at 6 months post-surgery.
Design: Retrospective cohort study.
Methods: Medical records of patients implanted with the SING IMT at two sites in Italy were reviewed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!